fda approved drugs and bioactive compounds Search Results


compound libraries comprising of fda-approved drugs, synthetic and semi-synthetic natural products as well as bioactives  (AnalytiCon Discovery GmbH)
90
AnalytiCon Discovery GmbH compound libraries comprising of fda-approved drugs, synthetic and semi-synthetic natural products as well as bioactives
Compound Libraries Comprising Of Fda Approved Drugs, Synthetic And Semi Synthetic Natural Products As Well As Bioactives, supplied by AnalytiCon Discovery GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/compound libraries comprising of fda-approved drugs, synthetic and semi-synthetic natural products as well as bioactives/product/AnalytiCon Discovery GmbH
Average 90 stars, based on 1 article reviews
compound libraries comprising of fda-approved drugs, synthetic and semi-synthetic natural products as well as bioactives - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
fda-approved drugs, synthetic and semisynthetic natural products as well as bioactives  (AnalytiCon Discovery GmbH)
90
AnalytiCon Discovery GmbH fda-approved drugs, synthetic and semisynthetic natural products as well as bioactives
Fda Approved Drugs, Synthetic And Semisynthetic Natural Products As Well As Bioactives, supplied by AnalytiCon Discovery GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fda-approved drugs, synthetic and semisynthetic natural products as well as bioactives/product/AnalytiCon Discovery GmbH
Average 90 stars, based on 1 article reviews
fda-approved drugs, synthetic and semisynthetic natural products as well as bioactives - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
fda-approved drugs, synthetic and semisynthetic natural products as well as bioactives  (MicroSource Discovery Systems)
90
MicroSource Discovery Systems fda-approved drugs, synthetic and semisynthetic natural products as well as bioactives
Fda Approved Drugs, Synthetic And Semisynthetic Natural Products As Well As Bioactives, supplied by MicroSource Discovery Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fda-approved drugs, synthetic and semisynthetic natural products as well as bioactives/product/MicroSource Discovery Systems
Average 90 stars, based on 1 article reviews
fda-approved drugs, synthetic and semisynthetic natural products as well as bioactives - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
fda approved drugs and bioactive compounds  (Topscience Co Ltd)
90
Topscience Co Ltd fda approved drugs and bioactive compounds
Identification of TDP25 degrader by high-throughput screening. (A) . Flowchart of the drug screening and its results. (B) . H4GT25 cells were pretreated with 1 μg/mL DOX (doxycycline) for 24 h, incubated with 2110 FDA approved drugs and <t>bioactive</t> compounds for 24 h, and the GFP-TDP25 fluorescence was analyzed by fluorescence microscopy and compared with cells treated with DMSO. The results were presented in the forms of scatter diagram. Skyblue and pink colors represent the degree of increase and decrease of GFP-TDP25 expression, respectively, following drug treatments. Shown in black scatterplot is MG132, and shown in red are ibudilast, ouabain, and SC75741. (C) . H4GT25 cells were pretreated with 1 μg/mL DOX for 24 h, treated with arsenite (0.5 mM) for 1 h, incubated with 178 hits for 24 h, and the GFP-TDP25 fluorescence was analyzed by fluorescence microscopy and compared with cells treated with DMSO. The results were presented in the forms of blue heatmap. (D) . H4GT25 cells were pretreated with 1 μg/mL DOX for 24 h, treated with MG132 (1 μM) for 12 h, incubated with 178 hits for 24 h, and the GFP-TDP25 fluorescence was analyzed by fluorescence microscopy and compared with cells treated with DMSO. The results were presented in the forms of red heatmap. (E) . H4GT25 cells were pretreated with 1 μg/mL DOX for 24 h, treated with arsenite (0.5 mM) for 1 h, and treated with ibudilast (10 μM), SC75741 (10 μM) or ouabain (10 μM) for another 24 h, fluorescence of GFP-TDP25 was analyzed by fluorescence microscopy and Cell viability was determined using CellTiterGlo ® assay (data represents Mean ± SD.; n = 8, **** p < 0.0001, *** p < 0.001, * p < 0.05, two-tailed t test). (F) . H4GT25 cells were pretreated with 1 μg/mL DOX for 24 h, treated with MG132 (1 μM) for 12 h, and treated with ibudilast (10 μM), SC75741 (10 μM) or ouabain (10 μM) for another 24 h, fluorescence of GFP-TDP25 was analyzed by fluorescence microscopy and Cell viability was determined using CellTiterGlo ® assay (data represents Mean ± SD.; n = 8, **** p < 0.0001, two-tailed t test). (G) . Chemical structure of SC75741.
Fda Approved Drugs And Bioactive Compounds, supplied by Topscience Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fda approved drugs and bioactive compounds/product/Topscience Co Ltd
Average 90 stars, based on 1 article reviews
fda approved drugs and bioactive compounds - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
fda-approved unique drugs and bioactive compounds nihcc lopac biomol iccb known bioactives microsource spectrum  (Biomol GmbH)
90
Biomol GmbH fda-approved unique drugs and bioactive compounds nihcc lopac biomol iccb known bioactives microsource spectrum
Identification of TDP25 degrader by high-throughput screening. (A) . Flowchart of the drug screening and its results. (B) . H4GT25 cells were pretreated with 1 μg/mL DOX (doxycycline) for 24 h, incubated with 2110 FDA approved drugs and <t>bioactive</t> compounds for 24 h, and the GFP-TDP25 fluorescence was analyzed by fluorescence microscopy and compared with cells treated with DMSO. The results were presented in the forms of scatter diagram. Skyblue and pink colors represent the degree of increase and decrease of GFP-TDP25 expression, respectively, following drug treatments. Shown in black scatterplot is MG132, and shown in red are ibudilast, ouabain, and SC75741. (C) . H4GT25 cells were pretreated with 1 μg/mL DOX for 24 h, treated with arsenite (0.5 mM) for 1 h, incubated with 178 hits for 24 h, and the GFP-TDP25 fluorescence was analyzed by fluorescence microscopy and compared with cells treated with DMSO. The results were presented in the forms of blue heatmap. (D) . H4GT25 cells were pretreated with 1 μg/mL DOX for 24 h, treated with MG132 (1 μM) for 12 h, incubated with 178 hits for 24 h, and the GFP-TDP25 fluorescence was analyzed by fluorescence microscopy and compared with cells treated with DMSO. The results were presented in the forms of red heatmap. (E) . H4GT25 cells were pretreated with 1 μg/mL DOX for 24 h, treated with arsenite (0.5 mM) for 1 h, and treated with ibudilast (10 μM), SC75741 (10 μM) or ouabain (10 μM) for another 24 h, fluorescence of GFP-TDP25 was analyzed by fluorescence microscopy and Cell viability was determined using CellTiterGlo ® assay (data represents Mean ± SD.; n = 8, **** p < 0.0001, *** p < 0.001, * p < 0.05, two-tailed t test). (F) . H4GT25 cells were pretreated with 1 μg/mL DOX for 24 h, treated with MG132 (1 μM) for 12 h, and treated with ibudilast (10 μM), SC75741 (10 μM) or ouabain (10 μM) for another 24 h, fluorescence of GFP-TDP25 was analyzed by fluorescence microscopy and Cell viability was determined using CellTiterGlo ® assay (data represents Mean ± SD.; n = 8, **** p < 0.0001, two-tailed t test). (G) . Chemical structure of SC75741.
Fda Approved Unique Drugs And Bioactive Compounds Nihcc Lopac Biomol Iccb Known Bioactives Microsource Spectrum, supplied by Biomol GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fda-approved unique drugs and bioactive compounds nihcc lopac biomol iccb known bioactives microsource spectrum/product/Biomol GmbH
Average 90 stars, based on 1 article reviews
fda-approved unique drugs and bioactive compounds nihcc lopac biomol iccb known bioactives microsource spectrum - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
compound libraries comprising of fda-approved drugs, synthetic and semi-synthetic natural products as well as bioactives  (MicroSource Discovery Systems)
90
MicroSource Discovery Systems compound libraries comprising of fda-approved drugs, synthetic and semi-synthetic natural products as well as bioactives
Identification of TDP25 degrader by high-throughput screening. (A) . Flowchart of the drug screening and its results. (B) . H4GT25 cells were pretreated with 1 μg/mL DOX (doxycycline) for 24 h, incubated with 2110 FDA approved drugs and <t>bioactive</t> compounds for 24 h, and the GFP-TDP25 fluorescence was analyzed by fluorescence microscopy and compared with cells treated with DMSO. The results were presented in the forms of scatter diagram. Skyblue and pink colors represent the degree of increase and decrease of GFP-TDP25 expression, respectively, following drug treatments. Shown in black scatterplot is MG132, and shown in red are ibudilast, ouabain, and SC75741. (C) . H4GT25 cells were pretreated with 1 μg/mL DOX for 24 h, treated with arsenite (0.5 mM) for 1 h, incubated with 178 hits for 24 h, and the GFP-TDP25 fluorescence was analyzed by fluorescence microscopy and compared with cells treated with DMSO. The results were presented in the forms of blue heatmap. (D) . H4GT25 cells were pretreated with 1 μg/mL DOX for 24 h, treated with MG132 (1 μM) for 12 h, incubated with 178 hits for 24 h, and the GFP-TDP25 fluorescence was analyzed by fluorescence microscopy and compared with cells treated with DMSO. The results were presented in the forms of red heatmap. (E) . H4GT25 cells were pretreated with 1 μg/mL DOX for 24 h, treated with arsenite (0.5 mM) for 1 h, and treated with ibudilast (10 μM), SC75741 (10 μM) or ouabain (10 μM) for another 24 h, fluorescence of GFP-TDP25 was analyzed by fluorescence microscopy and Cell viability was determined using CellTiterGlo ® assay (data represents Mean ± SD.; n = 8, **** p < 0.0001, *** p < 0.001, * p < 0.05, two-tailed t test). (F) . H4GT25 cells were pretreated with 1 μg/mL DOX for 24 h, treated with MG132 (1 μM) for 12 h, and treated with ibudilast (10 μM), SC75741 (10 μM) or ouabain (10 μM) for another 24 h, fluorescence of GFP-TDP25 was analyzed by fluorescence microscopy and Cell viability was determined using CellTiterGlo ® assay (data represents Mean ± SD.; n = 8, **** p < 0.0001, two-tailed t test). (G) . Chemical structure of SC75741.
Compound Libraries Comprising Of Fda Approved Drugs, Synthetic And Semi Synthetic Natural Products As Well As Bioactives, supplied by MicroSource Discovery Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/compound libraries comprising of fda-approved drugs, synthetic and semi-synthetic natural products as well as bioactives/product/MicroSource Discovery Systems
Average 90 stars, based on 1 article reviews
compound libraries comprising of fda-approved drugs, synthetic and semi-synthetic natural products as well as bioactives - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Identification of TDP25 degrader by high-throughput screening. (A) . Flowchart of the drug screening and its results. (B) . H4GT25 cells were pretreated with 1 μg/mL DOX (doxycycline) for 24 h, incubated with 2110 FDA approved drugs and bioactive compounds for 24 h, and the GFP-TDP25 fluorescence was analyzed by fluorescence microscopy and compared with cells treated with DMSO. The results were presented in the forms of scatter diagram. Skyblue and pink colors represent the degree of increase and decrease of GFP-TDP25 expression, respectively, following drug treatments. Shown in black scatterplot is MG132, and shown in red are ibudilast, ouabain, and SC75741. (C) . H4GT25 cells were pretreated with 1 μg/mL DOX for 24 h, treated with arsenite (0.5 mM) for 1 h, incubated with 178 hits for 24 h, and the GFP-TDP25 fluorescence was analyzed by fluorescence microscopy and compared with cells treated with DMSO. The results were presented in the forms of blue heatmap. (D) . H4GT25 cells were pretreated with 1 μg/mL DOX for 24 h, treated with MG132 (1 μM) for 12 h, incubated with 178 hits for 24 h, and the GFP-TDP25 fluorescence was analyzed by fluorescence microscopy and compared with cells treated with DMSO. The results were presented in the forms of red heatmap. (E) . H4GT25 cells were pretreated with 1 μg/mL DOX for 24 h, treated with arsenite (0.5 mM) for 1 h, and treated with ibudilast (10 μM), SC75741 (10 μM) or ouabain (10 μM) for another 24 h, fluorescence of GFP-TDP25 was analyzed by fluorescence microscopy and Cell viability was determined using CellTiterGlo ® assay (data represents Mean ± SD.; n = 8, **** p < 0.0001, *** p < 0.001, * p < 0.05, two-tailed t test). (F) . H4GT25 cells were pretreated with 1 μg/mL DOX for 24 h, treated with MG132 (1 μM) for 12 h, and treated with ibudilast (10 μM), SC75741 (10 μM) or ouabain (10 μM) for another 24 h, fluorescence of GFP-TDP25 was analyzed by fluorescence microscopy and Cell viability was determined using CellTiterGlo ® assay (data represents Mean ± SD.; n = 8, **** p < 0.0001, two-tailed t test). (G) . Chemical structure of SC75741.

Journal: Frontiers in Pharmacology

Article Title: SC75741, A Novel c-Abl Inhibitor, Promotes the Clearance of TDP25 Aggregates via ATG5-Dependent Autophagy Pathway

doi: 10.3389/fphar.2021.741219

Figure Lengend Snippet: Identification of TDP25 degrader by high-throughput screening. (A) . Flowchart of the drug screening and its results. (B) . H4GT25 cells were pretreated with 1 μg/mL DOX (doxycycline) for 24 h, incubated with 2110 FDA approved drugs and bioactive compounds for 24 h, and the GFP-TDP25 fluorescence was analyzed by fluorescence microscopy and compared with cells treated with DMSO. The results were presented in the forms of scatter diagram. Skyblue and pink colors represent the degree of increase and decrease of GFP-TDP25 expression, respectively, following drug treatments. Shown in black scatterplot is MG132, and shown in red are ibudilast, ouabain, and SC75741. (C) . H4GT25 cells were pretreated with 1 μg/mL DOX for 24 h, treated with arsenite (0.5 mM) for 1 h, incubated with 178 hits for 24 h, and the GFP-TDP25 fluorescence was analyzed by fluorescence microscopy and compared with cells treated with DMSO. The results were presented in the forms of blue heatmap. (D) . H4GT25 cells were pretreated with 1 μg/mL DOX for 24 h, treated with MG132 (1 μM) for 12 h, incubated with 178 hits for 24 h, and the GFP-TDP25 fluorescence was analyzed by fluorescence microscopy and compared with cells treated with DMSO. The results were presented in the forms of red heatmap. (E) . H4GT25 cells were pretreated with 1 μg/mL DOX for 24 h, treated with arsenite (0.5 mM) for 1 h, and treated with ibudilast (10 μM), SC75741 (10 μM) or ouabain (10 μM) for another 24 h, fluorescence of GFP-TDP25 was analyzed by fluorescence microscopy and Cell viability was determined using CellTiterGlo ® assay (data represents Mean ± SD.; n = 8, **** p < 0.0001, *** p < 0.001, * p < 0.05, two-tailed t test). (F) . H4GT25 cells were pretreated with 1 μg/mL DOX for 24 h, treated with MG132 (1 μM) for 12 h, and treated with ibudilast (10 μM), SC75741 (10 μM) or ouabain (10 μM) for another 24 h, fluorescence of GFP-TDP25 was analyzed by fluorescence microscopy and Cell viability was determined using CellTiterGlo ® assay (data represents Mean ± SD.; n = 8, **** p < 0.0001, two-tailed t test). (G) . Chemical structure of SC75741.

Article Snippet: All FDA approved drugs and bioactive compounds were commercially purchased from Topscience, Inc. (Shanghai, China).

Techniques: High Throughput Screening Assay, Drug discovery, Incubation, Fluorescence, Microscopy, Expressing, Two Tailed Test